| |
著者: John R Perfect, Kieren A Marr, Thomas J Walsh, Richard N Greenberg, Bertrand DuPont, Juliàn de la Torre-Cisneros, Gudrun Just-Nübling, Haran T Schlamm, Irja Lutsar, Ana Espinel-Ingroff, Elizabeth Johnson
雑誌名: Clin Infect Dis. 2003 May 1;36(9):1122-31. doi: 10.1086/374557. Epub 2003 Apr 22.
Abstract/Text
Treatments for invasive fungal infections remain unsatisfactory. We evaluated the efficacy, tolerability, and safety of voriconazole as salvage treatment for 273 patients with refractory and intolerant-to-treatment fungal infections and as primary treatment for 28 patients with infections for which there is no approved therapy. Voriconazole was associated with satisfactory global responses in 50% of the overall cohort; specifically, successful outcomes were observed in 47% of patients whose infections failed to respond to previous antifungal therapy and in 68% of patients whose infections have no approved antifungal therapy. In this population at high risk for treatment failure, the efficacy rates for voriconazole were 43.7% for aspergillosis, 57.5% for candidiasis, 38.9% for cryptococcosis, 45.5% for fusariosis, and 30% for scedosporiosis. Voriconazole was well tolerated, and treatment-related discontinuations of therapy or dose reductions occurred for <10% of patients. Voriconazole is an effective and well-tolerated treatment for refractory or less-common invasive fungal infections.
PMID 12715306 Clin Infect Dis. 2003 May 1;36(9):1122-31. doi: 10.1086/374557. Epub 2003 Apr 22.
|
